The mammary gland is composed of a complex cellular hierarchy with unusual postnatal plasticity. The identities of stem/progenitor cell populations, as well as tumour-initiating cells that give rise to breast cancer, are incompletely understood. Here we show that Lgr6 marks rare populations of cells in both basal and luminal mammary gland compartments in mice. Lineage tracing analysis showed that Lgr6 + cells are unipotent progenitors, which expand clonally during puberty but diminish in adulthood. In pregnancy or following stimulation with ovarian hormones, adult Lgr6 + cells regained proliferative potency and their progeny formed alveoli over repeated pregnancies. Oncogenic mutations in Lgr6 + cells resulted in expansion of luminal cells, culminating in mammary gland tumours. Conversely, depletion of Lgr6 + cells in the MMTV-PyMT model of mammary tumorigenesis significantly impaired tumour growth. Thus, Lgr6 marks mammary gland progenitor cells that can initiate tumours, and cells of luminal breast tumours required for efficient tumour maintenance.
The mammary gland consists of a bi-layered epithelium composed of luminal and basal (myoepithelial) mammary epithelial cells (MECs). Major mammary gland developmental steps occur postnatally, with extensive tissue remodelling during puberty and pregnancy 1 governed by stem/progenitor cells 2 . In vivo lineage tracing studies [3] [4] [5] [6] [7] [8] have revealed a highly complex mammary epithelial hierarchy. Transformation of different cells within this hierarchy results in phenotypically diverse breast tumours 9 , although in most cancer models the tumour-initiating cell (TIC) has not yet been identified.
The identity and in vivo properties of adult mammary gland stem cells (MaSCs) are controversial. MaSCs have been described as a basal population able to repopulate the whole mammary gland when transplanted [10] [11] [12] [13] . However, the ability of MaSCs to maintain both basal and luminal compartments postnatally has been disputed 3, 6 . Unipotent basal and luminal progenitors have been identified 6, 11, [13] [14] [15] , suggesting that postnatal progenitors may be lineage-restricted.
The leucine-rich repeat-containing G-protein coupled receptor 6 (Lgr6) marks stem cells of taste buds 16 , lung 17 and skin 18, 19 , as well as rare mammary gland cells 18 . However, whether Lgr6 also marks stem/progenitor cells in the mammary gland was unknown. Here we traced the fate of Lgr6-positive (Lgr6 + ) cells during postnatal mammary gland formation, homeostasis and pregnancy, and in murine models of basal and luminal breast cancer. We provide evidence that Lgr6 + cells are unipotent progenitors that contribute to alveologenesis and function as TICs for luminal mammary tumours.
RESULTS

Lgr6 marks clonogenic basal and luminal progenitor cells in postnatal mammary gland development
We analysed Lgr6 expression in MECs using Lgr6-EGFP-IRESCreERT2 reporter mice 18 (Lgr6-CreERT2) (Fig. 1a) . In 5-weekold virgin Lgr6-CreERT2 +/− mice, 2-4% of MECs were EGFP The lines at the top and bottom of the barcode show a cumulative enrichment of each set of genes (n = 6 mice pooled per replicate). P = 1 × 10 −7 (luminal progenitor), P = 1.58 × 10 −13 (basal progenitor) (by Wilcoxon two-sided gene set test). (d) qPCR analysis of mRNA expression between Lgr6 + and Lgr6 − cells (normalized to GAPDH) for genes characteristic of basal and luminal progenitor cells respectively (n = 3 mice). Mean ± s.d., * * * P < 0.001 (t-test). See Supplementary Table 2 for exact P values and source data.
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( Supplementary Fig. 1a ). RNA sequencing of fluorescence-activated cell sorting (FACS)-sorted Lgr6 + and Lgr6 − MECs showed differential expression of genes involved in mammary gland development (Fig. 1b) . The pool of Lgr6 + cells showed enrichment for previously described gene signatures of both basal and luminal mammary gland progenitor cells (Fig. 1c,d and Supplementary Fig. 1b) 4, 20, 21 . Consequently, we examined the clonal potential of Lgr6 + cells in prepubertal (2-week-old) and pubertal (4-week-old) Lgr6-CreERT2 +/− mice. We discovered basal and luminal Lgr6 + cells at both ages (Fig. 2a,b and Supplementary Figs 1c and 2a ). Using FACS, we detected a small fraction (4.5 ± 0.9%) of EGFP + MECs in pre-puberty (2 weeks, Fig. 2c ), containing mostly luminal (89.5 ± 4.0%) and fewer basal epithelial cells (10.5% ± 4.0%; Fig. 2a ). In pubertal mammary glands, we observed more basal (41.2 ± 11.7%) and fewer luminal EGFP + MECs (58.8 ± 11.7%) compared with pre-pubertal glands (Fig. 2b) . However, the overall percentage of EGFP + cells was not significantly altered (4.6 ± 0.9%, 4 weeks, Fig. 2c) .
To trace the progeny of Lgr6 + cells in vivo, we intercrossed Lgr6-CreERT2 mice with the Rosa26-tdTomato 22 reporter strain ('LT mice' , Fig. 2d ). We initiated lineage tracing in LT heterozygous females at pre-puberty and puberty (Fig. 2e) . Twenty-four hours after tamoxifen administration, we observed rare tdTomato + MECs (1.7 ± 0.2%, 2 weeks, and 0.9 ± 0.2%, 4 weeks). At both time points, the distribution of tdTomato + MECs corresponded to that of EGFP + cells ( Supplementary Fig. 2b ,c) and detection of traced cells was dependent on tamoxifen ( Supplementary Fig. 2d ,e). Multicellular clones of up to four cells appeared by 1 week post-induction and larger basalonly, as well as luminal-only, clones appeared thereafter ( Fig. 2f and Supplementary Fig. 2f ). The proportion of larger multicellular clones increased significantly over time (Fig. 2g,h ). The proportion of tdTomato + luminal clones remained greater than that of basal clones ( Supplementary Fig. 2g ) suggesting that basal and luminal Lgr6 + cells possess similar clonal potential pre-puberty.
Conversely, cells traced from puberty showed a stronger expansion of basal compared with luminal tdTomato + clones (Fig. 2i ,j and Supplementary Fig. 2h) . In rare cases, tdTomato + patches spanned both cell lineages (0.97-1.24%, following labelling in pre-puberty and puberty, respectively) ( Supplementary Fig. 2g-i) , and some Lgr6 + MECs at puberty co-expressed either Axin2 or Lgr5 messenger RNA, which may mark bipotential MaSCs ( Supplementary Fig. 2j ) [3] [4] [5] . However, apparently mixed clones were observed only after several weeks of tracing ( Supplementary Fig. 2g,h ), suggesting that fusion of adjacent tdTomato + basal and luminal clones could be responsible for the mixed cell patches. To test whether the Lgr6 + population contains rare, bipotent cells, we transplanted Lgr6 + basal cells into cleared fat pads ( Supplementary Fig. 2k ). Unlike basal MaSCs, Lgr6
+ basal cells were unable to reconstitute the mammary gland, indicating that they cannot adopt a multipotent fate. Our data are therefore consistent with 1w  8w 22w 52w  2w  1w  8w 22w 52w  2w   1w  8w 12w 16w 24w  4w   1w 8w 12w 16w 24w 4w 24w p.i. (4w) Figure 2 Two independent Lgr6 + progenitor cell populations contribute to postnatal mammary gland development. (a,b) Confocal images of Lgr6-CreERT2 +/− mammary glands at postnatal day 14 (P14) (a) and P30 (b). EGFP + cells are found in K14 + basal (arrows) and K14 − luminal cells (arrowheads). Scale bars, 25 µm. Bar graphs visualize the distribution of EGFP + cells with respect to MECs in 2-week-old (n=7 mice pooled from 2 independent experiments) (a) and 4-week-old (n = 10 mice pooled from 3 independent experiments) (b) Lgr6-CreERT2 +/− females as measured by flow cytometry. Mean ± s.e.m. (c) Box-and-whiskers plot showing the frequency of EGFP + MECs in Lgr6-CreERT2 +/− females at 2 weeks (w) and 4 weeks of age (n = 7 and n = 10 mice pooled from 2 and 3 experiments, respectively). Minima, maxima and median are indicated. NS, not significant; P = 0.673 (unpaired two-tailed t-test). (d) Lgr6-CreERT2 and Rosa26-tdTomato alleles ('LT mice') used for lineage tracing. CreERT2, tamoxifeninducible Cre recombinase; CAG, constitutively active hybrid promoter from cytomegalovirus and chicken β-actin promoters; STOP, stop cassette flanked by 2 loxP sites (black triangles); tdTomato, tandem dimer tomato red fluorescent protein. (e) Lineage tracing strategy in pre-puberty and puberty. TM, tamoxifen. (f) K14/K8 immunostaining of LT mammary glands at 22 weeks post-induction (p.i.) in pre-puberty (left panel) and 24 weeks p.i. in puberty (right panel). tdTomato + clones are found in the basal and luminal compartments. Scale bars, 20 µm. (g-j) Quantification of tdTomato + basal (g,i) and luminal (h,j) clone sizes at different time points post-induction. The graphs show the percentage of counted tdTomato + clones containing 1, 2-4, and >4 cells at each time point. (Number of analysed clones pooled from n = 3 mice per time point: n = 1,157, n = 344, n = 542, n = 645, n = 691, respectively, for g,h; n = 531, n = 1,476, n = 1,733, n = 163, n = 782, n = 597, respectively, for i,j. Mean ± s.e.m. * P < 0.05; * * P < 0.01; * * * P < 0.001 (one-way ANOVA)). See Supplementary Table 2 for source data for g-j.
unipotent Lgr6 + basal and luminal progenitors in the early postnatal mammary gland.
Basal and luminal Lgr6
+ progenitors contribute to the alveolar network during pregnancy
The generation of alveoli during repeated pregnancies requires longlived, multi-lineage or lineage-restricted progenitor cells [3] [4] [5] 7, 14, 23 . To test the contribution of Lgr6
+ progenitors to alveologenesis, we injected 4-week-old LT heterozygous females with tamoxifen and mated them 6 weeks later (Fig. 3a) . During pregnancy, tdTomato + patches were distributed over the whole mammary gland, consisting of basal tdTomato + cells as well as occasional, multicellular luminal clones in the expanding alveoli ( Supplementary Fig. 3a,b) . By the start of lactation, vast tdTomato + alveolar networks had formed ( Fig. 3b and Supplementary Fig. 3c,d ), mostly composed of labelled basal cells, and less frequently of luminal tdTomato + alveolar clones not associated with basal tdTomato + cells (Fig. 3c) , suggesting clonal expansion of unipotent basal or luminal progenitors. We rarely detected alveoli incorporating labelled basal and luminal cells ( Fig. 3d and Supplementary Fig. 3e ).
At day (d) 21 of involution, when most of the milk-producing epithelium has regressed, we found tdTomato + clones lining the mammary ducts and alveolar bud remnants ( Fig. 3e and Supplementary  Fig. 3f ), consisting mostly of basal cells ( Supplementary Fig. 3g ), and occasionally luminal cells (Supplementary Fig. 3h ).
Puberty-labelled LT heterozygous females subjected to multiple pregnancies displayed tdTomato-traced alveolar networks in all mammary glands. We identified large basal or luminal tdTomato + clones (Fig. 3f) , but saw no labelling spanning both compartments.
Thus, we concluded that pubertal Lgr6 + MECs comprise two separate populations of unipotent long-lived and self-renewing mammary gland progenitors clonally contributing to the alveolar network during pregnancy.
Lgr6
+ progenitors contribute minimally to adult mammary gland homeostasis and are continuously lost over time Consistent with the increased presence of basal clones at puberty, in 8-week-old virgin Lgr6-CreERT2 +/− females, EGFP expression was almost exclusively detected in basal MECs (93.5 ± 4.2%, Fig. 4a-c and Supplementary Fig. 4a ). EGFP + cells were found in primary and secondary ducts, including the distal tips of the ducts (Fig. 4a,b ) with a frequency (4.7 ± 2.9%) comparable to that of younger mice (Fig. 2c) . To test the clonal capacity of these cells in the virgin adult, we lineagetraced 8-week-old LT heterozygous females, labelling approximately 1.1% of MECs ( Fig. 4d and Supplementary Fig. 4b,c) . At 1 week post-tamoxifen, tdTomato labelled mostly single cells with occasional multicellular clones (Fig. 4e) . At 8 weeks post-tamoxifen, we detected very few basal tdTomato + clones ( Fig. 4f ) and after 22 weeks, multicellular tdTomato + clones had disappeared. The frequencies of tdTomato + MECs (0.28-0.60%) and EGFP + MECs (0.15%) also decreased ( Fig. 4g and Supplementary Fig. 4d,e) . Thus, Lgr6
+ cells do not play an obvious role in mammary gland homeostasis in adult virgin mice and their numbers decrease with age.
Mostly quiescent Lgr6-expressing cells can be reactivated by pregnancy or hormone treatment
To test the capacity of Lgr6 + cells to expand in the adult, we analysed pregnant females lineage-traced from 8 weeks (Fig. 5a) . Surprisingly, tdTomato + clones formed vast alveolar networks over the whole mammary gland at mid-pregnancy, with tdTomato + myoepithelial cells in ducts and alveoli (Fig. 5b) . Furthermore, we observed luminalonly labelled alveoli (Fig. 5c ), possibly derived from the small fraction of luminal EGFP + cells found in nulliparous adult mice (Fig. 4c) . Thus, pregnancy seems to re-awaken the clonogenic potential of both adult Lgr6 + MEC populations. As with lineage tracing from puberty, we observed sparse mixedlineage patches of tdTomato + cells in alveoli ( Supplementary Fig. 4f ) and in the main mammary ducts ( Supplementary Fig. 4g ) during the first pregnancy. However, over 97% of labelled alveoli were basalor luminal-only tdTomato + ( Fig. 5d ) and subsequent pregnancies revealed no alveoli labelled in both epithelial compartments.
To determine whether hormone stimulation activates Lgr6 + MECs in the adult, we treated females, labelled at 10 weeks, with subcutaneous 17β-oestradiol (E) and progesterone (P) pellets for 14 days. Although the frequencies of basal or luminal Lgr6 + MECs had not increased, we observed an expansion of luminal tdTomato + clones either with E/P or with E alone (Fig. 5e,f) . In line with this, we discovered luminal Lgr6
+ cells co-expressing oestrogen receptor alpha (ERα) (Fig. 5g) . Thus, pharmacologic stimulation with ovarian hormones induces the preferential expansion of luminal Lgr6 + progenitors.
Lgr6 is expressed in human breast cancers and its upregulation correlates with lower disease-free survival Tumour histological classification is based on expression of distinct hormonal receptors: ERα and/or progesterone receptor 1 (luminal), human epidermal growth factor receptor 2 (HER2-positive) or the absence of these markers (basal-like/triple-negative) [24] [25] [26] . In situ hybridization on over 500 human breast cancers detected Lgr6 expression in 49% of tumours (Fig. 6a ). Of these, around half were luminal, in agreement with publicly available data for breast cancers with Lgr6 upregulation 27, 28 ( Fig. 6b ). Disease-free survival in patients with high Lgr6 expression was significantly decreased over all tumour types compared with patients with low Lgr6 expression (Fig. 6c) , suggesting that Lgr6 overexpression correlates with tumour aggressiveness.
Lgr6
+ progenitors are potent TICs To test whether Lgr6 + cells can function as breast cancer TICs, we inactivated Trp53 and Brca1, two of the most commonly mutated breast tumour suppressors 29 
, in Lgr6
+ cells by generating Brca1 loxP/loxP :p53 loxP/loxP :Lgr6-EGFP-CreERT2 (BPL) mice (Fig. 6d ). Gene inactivation was triggered in 5-week-old mice by tamoxifen injection (Fig. 6e) . Initial K8-positive tumour lesions were detected at 10 weeks post-injection (Fig. 6f) . Subsequently, BPL animals developed mammary gland tumours expressing the luminal markers K8 and ERα (Fig. 6g) , demonstrating that oncogenic mutations in Lgr6 + cells can result in luminal cancer. We assessed the tumour-initiating potential of Lgr6 + cells in a second breast cancer model by deleting the F-box and WD repeat domain containing 7 (Fbxw7) tumour suppressor (commonly downregulated in luminal breast cancer 30, 31 ) in combination with activation of oncogenic K-Ras G12D in Lgr6 + cells (FRL mice) ( Supplementary Fig. 5a ,b). Oncogenic activation of Ras signalling occurs in over 20% of human breast carcinomas 32, 33 . FRL animals showed rapid tumour onset, with luminal lesions appearing at 3 weeks post-tamoxifen ( Supplementary  Fig. 5c ). At 8 weeks post-tamoxifen, mammary gland carcinomas expressing K8 and ERα were present ( Supplementary Fig. 5d ). In both FRL and BPL breast cancer models, 100% of analysed tumours arising from Lgr6 + cells were positive for K8, and despite the relatively low frequency of Lgr6 + MECs at 5 weeks of age, the tumour penetrance was high (BPL 60%, FRL 100%) ( Supplementary Fig. 5e ). Lgr6 + cells are therefore potent TICs for luminal mammary tumours.
Rare Lgr6
+ cells contribute clonally to luminal, but not basaloid, mammary tumours Mouse mammary tumour virus promoter-driven Polyoma virus middle T antigen (MMTV-PyMT ) is a well-established model of luminal breast cancer 34 , resulting in adenocarcinomas whose gene expression profile resembles that of luminal progenitor cells 20 . To investigate whether these tumours contain Lgr6
+ cells, we crossed the MMTV-PyMT strain with Lgr6 lineage-tracer mice to create the PLT model (Fig. 7a ). We identified rare Lgr6 + cells (2.3% ± 1.0% to 4.7% ± 1.0%) in normal and hyperplastic glands, and in tumours (Fig. 7b) . We traced Lgr6 + cell progeny in developing MMTVPyMT tumours after labelling PLT mice during pre-puberty and puberty (Fig. 7c) . At 12 days of age, small, isolated lesions were visible in PyMT +/− mammary glands ( Supplementary Fig. 6a,b) . Therefore, we administered tamoxifen between 9 and 12 days of age to label Lgr6 + cells before detectable tumour formation, resulting in a recombination efficiency similar to that seen in LT animals (1.5% of MECs). Hyperplastic regions at 2 weeks expressed PyMT protein independently of Lgr6 expression ( Supplementary Fig. 6c,d ).
Forty-eight hours after tamoxifen injection at 4 weeks, we observed tdTomato + cells adjacent to EGFP + /tdTomato + cells ( Supplementary  Fig. 6e ), indicating quickly dividing Lgr6 + cells. By administering 5-ethynyl-2 -deoxyuridine (EdU) to Lgr6-CreERT2 +/− :PyMT
mice of different ages, we confirmed a minor, but stable, population (between 7.2 ± 0.9% and 12.8 ± 4.9%) of cycling EGFP + cells in tumours ( Fig. 7d and Supplementary Fig. 6f ).
Multicellular tdTomato-expressing clones expanded over time when labelled at tumour onset (P12) and could occupy large areas of the tumour in fully grown carcinomas (Fig. 7e,f) . When labelled after tumour initiation (P28), tdTomato + clones continued to expand (Fig. 7g,h ). Very few tdTomato + cells retained expression of Lgr6, or expressed the gene de novo (Supplementary Fig. 6g ) and no tdTomato + cells were found in vehicle-treated control animals ( Supplementary  Fig. 6h ), indicating that rare Lgr6 + cells can expand from the earliest stages of tumour development and contribute to large portions of tumour mass.
Importantly, Lgr6 + cells contributed to the maintenance of fully developed MMTV-PyMT tumours, as demonstrated by labelling at 14 weeks ( Supplementary Fig. 6i ). As for lineage tracing at earlier stages, we were able to detect multicellular tdTomato + clones as early as 1 week post-induction ( Supplementary Fig. 6j ), which expanded until the mice were euthanized 7-10 weeks later (Supplementary Fig. 6k ).
Lgr6
+ MECs therefore contribute to increase the cell mass of MMTVPyMT-driven tumours throughout neoplastic development.
Since Lgr6 + cells are present in both MEC compartments, we asked whether they are also involved in basal mammary tumour formation. Transformation of basal cells by medroxyprogesterone acetate (MPA) and dimethylbenz[a]anthracene (DMBA) treatment results in basaloid and mixed-lineage tumours 35, 36 . We induced lineage tracing in Lgr6-CreERT2 +/− :Rosa26-tdTomato +/− females before, during and after MPA/DMBA treatment (Fig. 6i) . Although basal and luminal Lgr6 + cells were clearly detectable in MPA/DMBAtreated mammary glands ( Supplementary Fig. 6l ), we did not discover expanding tdTomato + clones in the resulting tumours, but only some K14 + /tdTomato + cells (Fig. 6j) . This result suggests that neither basal nor luminal Lgr6 + MECs are involved in MPA/DMBA-induced basal tumorigenesis.
+ cells sustain tumour growth and display characteristics of TICs
The tumour-forming capacity of Lgr6 + cells, together with their contribution to tumour expansion, suggests that they have TIC properties. To assess whether Lgr6 + cells are resistant to chemotherapy, another TIC characteristic, we treated labelled tumour cells from PLT mice in organoid culture with doxorubicin ( Supplementary Fig. 7a ). The proportion of tdTomato + cells within labelled organoids increased after doxorubicin treatment when compared with untreated cells (Supplementary Fig. 7b,c) , suggesting that Lgr6 + progeny are more resistant to chemotherapy. To directly test the requirement for Lgr6 cells in MMTV-PyMT tumours, we assessed the consequences of Lgr6 + cell depletion, using MMTV-PyMT:Lgr6-EGFP-CreERT2 (PL) mice crossed to a Rosa26-LSL-diphtheria toxin receptor (DTR) strain to create the PDL model (Fig. 8a) . We treated PDL animals every other week between two and ten weeks of age with alternate injections of tamoxifen and diphtheria toxin (DT) (Fig. 8b) . Depletion of Lgr6 + cells by DT injection was efficient, indicated by a reduction in EGFP + cells and reduced tumour cell proliferation in PDL animals compared with controls (Fig. 8c,d) .
Tumour onset was delayed in PDL mice (Fig. 8e) , confirming that Lgr6 + cells contribute to tumour outgrowth. Importantly, depletion of Lgr6
+ cells resulted in a dramatic change in tumour histology. Table 2 for source data for e,h.
Control PL tumours showed a solid architecture, morphologically undifferentiated tumour cells, and a high mitotic index, as reported for the MMTV-PyMT model. In contrast, PDL tumours had a dominant dilated ductal and acinar phenotype with well-differentiated elements, fewer undifferentiated cells, and less mitotic activity than controls (Fig. 8f) .
To further explore the capacity of Lgr6 + cells to maintain tumour growth, we isolated tumour cells from untreated PDL animals. Application of DT to cultured primary tumour cells resulted in decreased Lgr6 mRNA levels, consistent with substantial depletion of Lgr6 + cells ( Supplementary Fig. 7d,e) . DT-treated cells had a reduced ability to form spheres compared with untreated cells (Supplementary Fig. 7f ). To test the requirement for Lgr6
+ cells in vivo, we injected Nu/Nu mice with equal numbers of DT-treated and untreated cells (Fig. 8g) . Tumours derived from DT-treated cells were significantly smaller (Fig. 8h) and showed a differentiated tumour morphology similar to that observed in DT-treated PDL animals ( Supplementary Fig. 7g ).
These observations show that Lgr6 + cells promote sphere-forming capability, are resistant to chemotherapy, sustain tumour growth and are necessary to recreate the normal tumour histology, all characteristics of TICs.
DISCUSSION
Our study describes multiple functions of Lgr6
+ cells in the mammary gland during postnatal development, pregnancy and cancer ( Supplementary Fig. 8 ).
We identified two epithelial mammary gland progenitor populations marked by Lgr6 that contribute to organ development, in the basal and luminal compartments, respectively. The proportion of Lgr6 + cells remains stable during postnatal development, but declines in adulthood, correlating with reduced clonal expansion in virgin mice. Pre-puberty, most Lgr6 + cells are luminal, but the basal Lgr6 + population expands more during puberty and by adulthood, the majority of Lgr6 + cells are basal. Lgr6 + cells contribute to ductal morphogenesis during postnatal development, and although they do not play an obvious role in tissue homeostasis, adult Lgr6 + cells can 'reactivate' and sustain alveologenesis throughout multiple pregnancies.
Our clonal analysis showed that Lgr6 + cell progeny are almost exclusively restricted to a single compartment. Adjacent basal and luminal lineage-traced cells were undetectable in the first few weeks post-labelling in pre-puberty and puberty. Rare mixedlineage tdTomato + patches were observed only when traced into adulthood or alveologenesis in pregnancy, periods of massive epithelial expansion 37, 38 . Fig. 2k ). Thus, while our observations do not exclude the existence of bipotential MaSCs 5,40 , our data support a unipotent progenitor model for Lgr6
+ MECs, which is further substantiated by recent data 41 .
Luminal Lgr6
+ cells contribute to alveologenesis independently of basal SCs, and are reminiscent of hormone receptor-negative, parity-identified MECs (PI-MECs) 14, 15 . On the other hand, their high clonogenic capabilities at peak oestrogen levels (in puberty and pregnancy) resemble the typical proliferative pattern of hormone receptor-expressing cells 42, 43 . The existence of ERα-positive luminal progenitor cells is disputed 44 , but has been described based on label-retaining experiments 23 + cells, p53/Brca1 loss and K-Ras activation/Fbxw7 loss, gave rise only to luminal tumours. The combination of p53 and Brca1 loss typically results in tumours with a basal phenotype, with only a minor proportion of luminal tumours [47] [48] [49] , but only K8-positive lesions were observed in our model. Brca1/p53 tumours originate from the luminal compartment and then switch to a basal phenotype 50 .
It is therefore possible that the Lgr6
+ population is incapable of such a switch and, when mutated for Brca1 and p53, gives rise to luminal tumours. This interpretation raises the possibility that the cell of origin, but not the combination of oncogenes, is the primary determinant of tumour type in these models.
Consistent with Lgr6 + progenitor cells and bipotential MaSCs being separate populations, Lgr6 + cell progeny did not contribute to basaloid DMBA/MPA-induced mammary tumours 35 , in which basal MaSCs are the presumed targets of chemical transformation 36, 51, 52 . In contrast, fate mapping showed that luminal Lgr6 + progenitor cells contribute to early tumour outgrowth in PyMT-induced luminal tumours. The MMTV promoter is predominantly active in the luminal compartment 53, 54 and most pre-pubertal Lgr6 + MECs are of a luminal nature. These observations are supported by recent studies [55] [56] [57] showing that lineage-restricted luminal stem cells can initiate mammary tumours. Lgr6 + cells also play an important role in conferring tumour aggressiveness in the MMTV-PyMT model, since Lgr6 + cell-depleted tumours were more differentiated and less proliferative. Lgr6 + cells are self-sustaining, fuel tumour growth, and strongly affect the composition of the tumour, characteristics of TICs. As current efforts to target TICs often rely on very broad and nonspecific markers 58 , characterization of this rare Lgr6
+ cell pool will benefit research into TIC-targeting therapies.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. Fig. 8 were mice lacking either the Cre recombinase or the diphtheria toxin receptor allele. No randomization methods were used in the in vivo experiments, and the investigators were not blinded to allocation during experiments and outcome assessment. No statistical method was used to predetermine sample size.
For this study, we used only female mice, which were between 12 days and 9 weeks of age at the start of experiments.
For tracing experiments, a single dose of 1 mg tamoxifen (Sigma) in 50 µl sunflower oil (Sigma) was injected intraperitoneally into 2-week-old mice. Fourweek-old females received 1.5 mg or 2 mg tamoxifen in 75 µl or 100 µl volume, respectively. These doses were reported not to interfere with normal mammary epithelial cell proliferation 3 . For Cre induction at later time points, we injected 5 mg tamoxifen in 250 µl oil. For depletion experiments, mice were injected with 100 µg g −1 body weight tamoxifen once daily for three consecutive days once every two weeks between the ages of 2 and 10 weeks. Tamoxifen (Sigma-Aldrich) was dissolved in peanut oil (Sigma-Aldrich).
We controlled for potential tamoxifen effects on mammary gland development and as shown by others 3, 56, 64 , tamoxifen administration transiently delayed the outgrowth of the epithelium during puberty. However, this delay in outgrowth was reversed by the time the mice reached adulthood.
Mice for depletion experiments were injected intraperitoneally with 12 ng g −1 body weight diphtheria toxin (Sigma-Aldrich) once daily for three consecutive days once every two weeks between the ages of 2 and 10 weeks. EdU labelling. EdU (Invitrogen) was injected intraperitoneally at 0.2 mg 10 g −1 body weight and mammary glands were harvested 3 h after injection. EdU incorporation was visualized using a Click-iT Imaging kit (Invitrogen).
MPA/DMBA treatment. Mice were anaesthetized using ketamine-xylazine, and slow-release (90 days) MPA pellets (50 mg; Innovative Research of America) were subcutaneously implanted on the right flank. DMBA (100 µl, 10 mg ml −1 in sunflower oil; Sigma) was administered six times by oral gavage over the next 8 weeks as described in Fig. 7i .
Pharmacological stimulation with ovarian hormones. Mice were anaesthetized with isoflurane (Baxter), and slow-release (90 days) MPA and/or 17β-oestradiol pellets (50 mg and 0,72 mg, respectively; Innovative Research of America) were subcutaneously implanted in the right flank.
Immunofluorescence and immunohistochemistry staining. Mice were euthanized by cervical dislocation and the mammary glands were dissected out. Dissected mammary glands were pre-fixed in 4% paraformaldehyde for 30-60 min at room temperature to preserve native fluorescence. Tissues were washed with phosphatebuffered saline (PBS), embedded in optimal cutting temperature compound (OCT; Tissue-Tek) and stored at −80 • C.
For whole-mount immunostaining, mammary glands were thawed and washed twice with PBS for 1 h. The tissue was permeabilized with two washes of PBS0.5T (PBS + 0.5% v/v Triton X-100) for 1 h. For immunostaining, the samples were incubated overnight at 4 • C with primary antibodies diluted in PBD0.2T (PBS + 1%BSA + 1% v/v dimethylsulfoxide + 0.2% v/v Triton X-100). The next day, they were washed four times with PBD0.2T for 1 h. Tissues were incubated with secondary antibodies plus DAPI (4 ,6-diamidino-2-phenylindole; Roche) or TO-PRO-3 (Life Technologies) at 4 • C overnight. After four washes with PBD0.2T for 1 h, tissues were optically cleared in 80% glycerol in PBS at room temperature. The stained mammary glands were mounted between two coverslips and sealed with silicone. Mammary glands from pregnant mice were cut into smaller pieces with scalpels prior to mounting.
For whole-mount staining of the F-actin cytoskeleton, mammary glands were permeabilized with PBS0.5T for 2 h and incubated overnight at 4 • C with Alexa 647-linked phalloidin (1:100; Invitrogen) and DAPI diluted in PBS0.5T, followed by optical clearing with 80% glycerol.
For confocal analysis of thick tissue sections, mammary gland sections of 100-150 µm were cut using a cryostat (Leica Biosystems) and OCT was washed off with warm (37 • C) PBS. The sections were permeabilized for 1 h with PBS0.5T and incubated overnight at 4 • C with primary antibodies diluted in PBD0.2T. The next day, they were washed four times with PBD0.2T for 15 min. Tissues were incubated with secondary antibodies at 4 • C overnight and washed four times with PBD0.2T for 15 min. DAPI or TO-PRO-3 was added to the last washing step. The stained mammary gland sections were mounted in ProLong Gold (Life Technologies) between two coverslips.
For immunohistochemistry, mammary glands were fixed overnight in 10% neutral buffered formalin, then washed with 70% ethanol, processed and embedded into paraffin. Sections were cut 4 µm thick and deparaffinized in Histo-Clear (National Diagnostics), rinsed in ethanol and washed in water and PBS. Sections were stained with H&E or with antibodies for immunohistochemistry. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 5 min followed by washes with PBS. Epitope blocking was performed for 1 h at room temperature with blocking solution: 1% bovine serum albumin (Sigma-Aldrich), 5% normal donkey serum (EMD-Millipore) and 0.4% Triton X-100 (SigmaAldrich) diluted in PBS. Sections were then incubated overnight at 4 • C with primary antibodies diluted in blocking solution. The next day, sections were washed with PBS and incubated for 2 h at room temperature with secondary antibodies (Life Technologies) diluted in blocking solution, then washed again and staining was visualized with 3,3 -diaminobenzidine (DAB) followed by counterstaining with Mayer's haematoxylin. The sections were then dehydrated and mounted.
Antibodies used were against keratin 8 (DSHB; TROMA-I, 1:500), keratin 14 (Abcam; Ab9220, 1:500), GFP (Abcam; Ab13970, 1:250), keratin 5 (Abcam; Ab52635, 1:500), oestrogen receptor alpha (Santa Cruz; sc-542, 1:200), Ki67 (Abcam; Ab16667, 1:200), CD49f (BD Pharmingen, 555734, 1:100), anti-middle T oncogene (Santa Cruz; sc-53481, 1:100). All secondary antibodies were biotinylated, horse radish peroxidase (HRP)-conjugated, or Alexa-conjugated antibodies (Molecular Probes, 1:330): goat anti-rat A405, goat anti-rabbit A488, goat anti-chicken A488, donkey anti-rabbit A488, goat anti-rat A546, goat anti-rabbit A647, goat antirat A647.
Microscopic imaging. Confocal images were acquired using Zeiss LSM710, LSM780 or LSM880 confocal microscopes (Carl Zeiss Microscopy). Water immersion lenses (20×, W Plan-Apochromat, 1.0 numerical aperture; and 40×, C-Apochromat, 1.2 numerical aperture) were used to record optical sections at 1,024 × 1,024 or 2,048 × 2,048 pixels and data were processed using Zeiss AxioVision or ZEN software. Images were converted to RGB images with ImageJ software.
Quantification immunohistochemistry. For Ki67 quantification, 10 regions were randomly chosen per slide at ×40 magnification and from at least three different animals. The number of Ki67-positive cells was counted against the total number of cells in each region.
Tissue preparation for histological analysis and in situ hybridization (ISH). Tissues were fixed overnight in 4% paraformaldehyde and paraffin-embedded according to standard techniques.
For haematoxylin and eosin staining as well as for ISH, paraffin-embedded mammary glands were cut into 4 µm sections using a microtome (Leica Biosystems). Haematoxylin and eosin staining was performed using a standard protocol.
In situ hybridization. In situ hybridization for Lgr6 RNA transcripts was performed using the RNAscope 2.0 High Definition assay and for double ISH against Lgr6 and Axin2 RNA or Lgr6 and Lgr5 RNA, we used the RNAscope 2-Plex Chromogenic kit (Advanced Cell Diagnostics). All assays were performed according to the manufacturer's instructions using specific probe sets against murine Lgr6 (Probe: Mm-Lgr6), murine Lgr5 (Probe: Mm-Lgr5-C2) and murine Axin2 (Probe: MmAxin2-C2). As positive and negative controls, we used the RNAscope Mm-Polr2a (312471) and dapB (310043) control probe sets.
We performed RNA ISH for Lgr6 mRNA expression in mammary glands from untreated and tamoxifen-treated mice. According to our experiments, tamoxifen administration does not obviously affect the expression pattern of Lgr6 mRNA.
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Disease-free survival analysis. The RNA-seq data of 1,100 invasive breast carcinoma patients were obtained from the cBio Cancer Genomics Portal (http://cbioportal.org) and ref. 59 . Disease-free survival analysis was then performed using the cBioPortal web tool set with a z-score threshold of ±3.
RNA sequencing (RNA-seq). Lgr6-positive and -negative cells from two different replicates, each composed of six animals, were FACS-sorted and RNA recovered by MagMAX Total RNA isolation kit (Life Technologies). RNA concentrations were determined with a Qubit fluorometer (ThermoFisher) as 7-25 pg µl −1 before analysis of RNA quality on a bioanalyser (Agilent) (RIN 5-8) . cDNA (50-75 ng µl −1 ) was generated from 5 µl RNA (NuGEN/Next-Gen), sheared (Covaris S-series), and cDNA fragments were cleaned up (Zymo Research) before 10 ng was used to generate an amplified cDNA library (NuGEN Ovation) over 18 PCR cycles. cDNA was sequenced on a HiSeq 2500 system (Illumina) in paired-end 50 mode.
RNA-seq analysis. Gene level abundance estimates were generated using RSEM (v1.2.22) 65 by mapping 50 bp paired-end reads against the Mus musculus mm10 Refseq transcriptome and reference genome with the STAR (v2.4.2a) 66 aligner. Normalization factors were calculated using the MedianNorm function from the Bioconductor package EBSeq (v1.8.0). The posterior probability of differential gene expression was assessed using the EBTest (maxround = 5) and GetDEResults (FDR = 0.01) functions also from EBSeq.
Expression profiles of normalized abundance estimates were presented as heatmaps. A count of 1 was added to all normalized read counts prior to converting to a log base 2 scale. Genes were clustered using a Euclidean distance metric and complete agglomeration method. Genewise counts were converted to z-scores by subtracting the mean and dividing by the standard deviation to aid visualization.
A Wilcoxon two-sided gene set test was used to look for enrichment of known luminal (n = 55) and basal (n = 469) progenitor genes within a rank ordered list of 15,902 gene posterior fold changes 4, 20, 21 .
Tumour sphere cultivation and treatment. Mammary glands from PDL mice were dissected, mashed gently with a MACS dissociator (Miltenyi Biotec) and incubated in HBSS with 300 U ml −1 collagenase (Sigma) plus 300 µg hyaluronidase (300 U ml −1 activity) (Sigma) and digested for 30 min at 37 • C. Red blood cells were lysed and samples digested with trypsin for 3 min at 37 • C before being filtered with a 70 by 40 µm mesh. Cells (9 to 15 × 10 6 ) were then plated onto collagen (Sigma-Aldrich)-coated 150 mm dishes and incubated overnight at 37 • C in DMEM F12 (Gibco) plus L-glutamine, 2% FBS, 1% penicillin/streptomycin, 10 µg ml −1 insulin, 20 µg ml −1 EGF (Peprotech). Medium was replaced 24 h later with DMEM F12 (50 ml), 1 ml B27 (STEMCELL) (50×), 20 ng ml −1 EGF and FGF (Peprotech), 4 µg ml −1 heparin, 1% penicillin/streptomycin. Cells were then treated with 4-hydroxytamoxifen (SigmaAldrich) at a final concentration of 0.25 µM for 3 days. After washing away the 4-hydroxytamoxifen, cells were treated with or without diphtheria toxin (25 ng ml −1 ) for 3 days. After treatment, cells were harvested and equal numbers of treated and non-treated cells were re-plated by serial dilution onto ultralow-attachment plates. Colony formation was assessed 8 to 10 days after plating.
Tumour organoid cultivation and treatment. Briefly, mammary gland tissue was isolated and collagenase digested as described for the isolation of tumour spheres. The digestion mixture was washed three times with PBS and organoids were separated from single cells by four differential centrifugation steps 67 . Organoids were plated in growth factor reduced Matrigel (BD Biosciences) on ultralow-attachment cell culture dishes (Corning) and cultivated in murine organoid media (MEBM, Lonza) containing B27 growth supplement (STEMCELL), 20 ng ml −1 rhEGF and rhbFGF, 4 µg ml −1 heparin (Santa Cruz) and 1% penicillin/streptomycin.
Organoids were treated for 48 h with 2 µM doxorubicin (Sigma). After treatment, the organoids were washed three times with PBS and allowed to recover for 12 days.
FACS. Cells for FACS were isolated from mammary glands as described above for the tumour sphere isolation protocol. Three to eight million cells were incubated in 250 µl 2% FBS/PBS with primary antibodies for 30 min on ice, with gentle agitation by flicking every 5 min. Primary antibodies were washed with 2% FBS/PBS, and cells incubated for 30 min with secondary antibodies on ice in the dark. Primary antibodies employed were: anti-CD24-PeCy7 (BD Biosciences no. 101822, 1:50), anti-CD29-Alexa-647 (BD Biosciences no. 102214, 1:100), anti-CD45-Pacific blue (BD Biosciences no. 103126, 1:100), anti-CD31-Pacific blue (BD Biosciences no. 102422, 1:100), anti-Ter119-Brilliant violet (BD Biosciences no. 562774, 1:100), biotinylated anti-CD45, anti-CD31, anti-Ter119 (clones 30F-11, 390, TER-119; eBioscience: catalogue no. 13-0451, no. 13-0311, no. 13-5921, all 1:100), anti-CD24-PerCP-Cy5.5 (clone M1/69; BD Pharmingen: catalogue no. 562360, 1:50), anti-CD29-Pe-Cy7 (clone HMb1-1; eBioscience, catalogue: no. 25-0291-82, 1:100) and Streptavidin-V450 (BD Biosciences, catalogue no. 560797, 1:100). DAPI or SytoxRed was added to exclude dead cells. Data analysis and cell sorting was performed on a FACSAria sorter and LSRFORTESSA II flow cytometer using the FACS DiVa software (BD Biosciences). LIN − population was isolated by exclusion of CD451/CD311/CD140α-positive cells. Cell populations were quantified as an average (±s.d.) of at least three experiments (employing at least three animals per group per experiment). Data were analysed using FlowJo software (FLOWJO, LLC).
Cleared fat pad transplantation. EGFP + or EGFP − lin − CD29 hi CD24 + cells were sorted into HBSS/2%FBS, spun down and resuspended in a mixture of HBSS/2%FBS and Matrigel (1:1). The cells were injected into the cleared no. 4 fat pads of 21-dayold NOD/SCID females.
Quantitative RT-PCR. RNA was isolated from dissected mammary gland cells or FACS-sorted cells using the Qiagen Micro-RNA kit (Qiagen) or the MagMAX Total RNA isolation kit (Life Technologies). The cDNA was generated using the Transcriptor First Strand cDNA synthesis kit (Roche Diagnostics) and was used for qPCR SYBR-green (Life Technologies) detection using the primers listed in Supplementary Table 1 .
Quantification of the number and size of clones traced in the mammary gland. Three independent mice were analysed for each time point. For each traced mammary duct area, the size and keratin expression (K14 + or K8 + ) of tdTomato + clones was recorded. The clones were grouped according to size (1 cell, 2-4 cells, >4 cells) and their frequency was calculated versus the total number of traced clones.
We defined clones as single tdTomato + cells or clusters of one or more cells that contacted each other 3 . We excluded extensively traced areas, in which the discrimination between basal and luminal cells was impeded.
Quantification of tdTomato + tumour area. For each analysed mammary gland or tumour, 3-4 100-µm-thick longitudinal sections were stained with TO-PRO3 and whole tissue sections were recorded by confocal microscopy. ImageJ software was used to outline and measure the total tissue area and the tdTomato + tissue area and the percentage of the tdTomato + area was calculated.
Statistics and reproducibility. Data were analysed using GraphPad Prism software (GraphPad Software) and are presented as the mean with s.e.m or s.d. (as indicated in figure legends). For box-and-whisker plots, data are presented as the median with highest and lowest values. Multiple groups were tested using analysis of variance (ANOVA) and comparisons between two groups were performed using t-tests. P < 0.05 was considered statistically significant. Asterisks indicate levels of significance ( * , P < 0.05; * * , P < 0.01; * * * , P < 0.001).
EdU detection was repeated at least three times per labelling time point. Immunohistological and immunofluorescence stainings were repeated at least three times. In situ hybridization was repeated at least three times for each probe. FACS analysis and tumour sphere experiments were performed at least three times.
Data availability. RNA sequencing data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE75648. Previously published RNA-seq data of 1,100 invasive breast carcinoma patients were obtained from the cBio Cancer Genomics Portal (http://cbioportal.org) and ref. 59 .
Source data for Fig. 1d, Fig. 2g-j, Fig. 4g, Fig. 5f, Fig. 7d ,f,h and Fig. 8e ,h, and Supplementary Fig. 7c ,e,f have been provided as Supplementary Table 2. All other data supporting the findings of this study are available from the corresponding authors on request.
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